Clinical trial number NCT01627379 for "Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable, Advanced or Metastatic Esophageal Squamous Cell Cancer" at ClinicalTrials.gov
Clinical trial number NCT00460265 NCT00460265 for "I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations" at ClinicalTrials.gov
Clinical trial number NCT00460265 NCT00460265 for "Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer" at ClinicalTrials.gov
Clinical trial number NCT02162563 for "Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases" at ClinicalTrials.gov
Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, et al. (March 2010). "Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer". Journal of Clinical Oncology. 28 (8): 1351–7. doi:10.1200/JCO.2008.21.7828. PMID20142600. S2CID30651519.
Ma P, Yang BB, Wang YM, Peterson M, Narayanan A, Sutjandra L, et al. (October 2009). "Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors". Journal of Clinical Pharmacology. 49 (10): 1142–56. doi:10.1177/0091270009344989. PMID19723673. S2CID25766549.
Gibson TB, Ranganathan A, Grothey A (May 2006). "Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer". Clinical Colorectal Cancer. 6 (1): 29–31. doi:10.3816/CCC.2006.n.01. PMID16796788.
Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, et al. (March 2010). "Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer". Journal of Clinical Oncology. 28 (8): 1351–7. doi:10.1200/JCO.2008.21.7828. PMID20142600. S2CID30651519.
Ma P, Yang BB, Wang YM, Peterson M, Narayanan A, Sutjandra L, et al. (October 2009). "Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors". Journal of Clinical Pharmacology. 49 (10): 1142–56. doi:10.1177/0091270009344989. PMID19723673. S2CID25766549.
Gibson TB, Ranganathan A, Grothey A (May 2006). "Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer". Clinical Colorectal Cancer. 6 (1): 29–31. doi:10.3816/CCC.2006.n.01. PMID16796788.
Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, et al. (March 2010). "Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer". Journal of Clinical Oncology. 28 (8): 1351–7. doi:10.1200/JCO.2008.21.7828. PMID20142600. S2CID30651519.
Ma P, Yang BB, Wang YM, Peterson M, Narayanan A, Sutjandra L, et al. (October 2009). "Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors". Journal of Clinical Pharmacology. 49 (10): 1142–56. doi:10.1177/0091270009344989. PMID19723673. S2CID25766549.